跳至主要内容
临床试验/NCT01095744
NCT01095744已完成不适用

Influence of Age on amyloïd Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease Like Posterior Cortical Atrophy (PCA) and Logopenic Progressive Aphasia (LPA)Using Positron Emitting Tomography (PET) Imaging

Institut National de la Santé Et de la Recherche Médicale, France1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
PIB-PET imaging of amyloid load

研究概览

简要总结

The first objective is to asses influence of age on amyloid load measured by PET imaging using Pittsburgh B compound (PiB) radio-tracer, in Alzheimer's disease(AD). This will allow the determination of brains age-specific deterioration factors by comparing Early onset AD (EOAD), Late onset AD (LOAD)and atypical focal cortical AD (PCA and LPA). The amount of brain lesions in AD patients is estimated by:

  1. measuring the rate of cortical brain atrophy,
  2. FDG imaging of glucose metabolism reflecting neuronal activity, and
  3. for patients who benefited from a lumbar puncture; Cortical-spinal fluid (CSF) amounts of amyloïd and tau proteins are measured.

详细描述

Literature data suggests there are different types of AD depending on their age of onset, called EOAD and LOAD. These two categories are distinguished by the localization of brain atrophy : severe and 'posterior' in EOAD and more 'anterior' in LOAD. Neuro-pathologic data suggests some atypical focal cortical atrophy, characterized by a respect of episodic memory, may be classified within EOAD.

PiB-based PET imaging allows the in-vivo visualization and quantification of amyloïd load.

We want to answer the question whether the amount of amyloïd protein may be lower in LOAD than EOAD in patients showing the same level of dementia, and thus identify ageing-specific cognitive disorders and understand witch factors influence etio-pathology of typical and atypical Alzheimer's disease.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • AD patients: clinical dementia rating between 0.5 and 2 free and cued recall test (Grober and Buschke) cued-recall < 18/48 and total recall < 40/48
  • atypical AD : i visual-spatial disorder and respect of episodic memory progressive evolution, Balint syndrome ii progressive language disorder constituted of logopenic aphasia respect of episodic memory
  • controls: age over 30 MMSE over or equal to 27 normal neuropsychiatric state for age and education level

排除标准

  • for every patients : psychiatric disorders age under18 absence of social security counter indication to MRI supposed or actual alcoholism or drug addiction pregnancy

结局指标

主要结局

PIB-PET imaging of amyloid load

时间窗: 0 - 2 months

PET imaging using PIB radio-tracer will give an estimation of regional amyloid load for every patient

FDG-PET imaging of glucose metabolism

时间窗: 0 - 2 months

PET imaging using 18F-fluorodesoxyglucose (FDG) will give a visualization of regional neuronal metabolism

clinical phenotypic assessment

时间窗: 0 - 2 months

the clinical evaluation includes a neurologic consulting, a neuropsychologic assessment of cognitive performances, and evaluation of autonomy

MRI

时间窗: 0 - 2 months

the magnetic resonance imaging will be performed using numerous modalities like T1 weighted sequences for anatomic information, T2 weighted FLAIR and TSE sequences to avoid vascular injuries and T2 GRE to avoid microbleeds, DTI for the diffusion tensor imaging and default mode FMRI, to identify neural networks involved in default concious mode.

ApoE gene sequencing

时间窗: 0 - 24 months after inclusion

ApoE gene sequencing, will be performed after all samples have been collected. So this may be 0 to 24 month after inclusion.

次要结局

  • amyloid and Tau measurements in cerebro-spinal fluid (csf)(-6 months or +6months arround T0)

研究者

发起方
Institut National de la Santé Et de la Recherche Médicale, France
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Influence of Age on Amyloid Load in Alzheimer's... | 临床试验